It's getting ugly out there..

The FDA's conditional approval of Aducanumab has not gone over well.  As we noted before, the approval was over the objection of the FDA's independent advisory panel, and now three of the 11 members have quit in anger over the decision.   

And that anger is spreading.  Some activists are calling for the resignation of Janet Woodcock, the FDA's acting Commissioner.  Who knows where that will end up.

Biogen's stock price has held on to its dramatic gains that followed the FDA's approval.  But I notice some analysts have begun to call it "overvalued."  We'll see what happens with all of this.